Digital Desk, New Delhi. The Drugs Controller General of India (DCGI) has approved the second and third phase clinical trials of the Sputnik-5 vaccine made by Russia to Indian pharmaceutical manufacturer Dr. Reddy’s Laboratories. On September 16, the Russian Direct Investment Fund (RDIF) and Dr. Reddy’s Laboratories Limited had agreed to collaborate on clinical trial (clinical) trials and delivery of the Sputnik-5 Kovid-19 vaccine in India.
The Sputnik-5 vaccine has been developed jointly by the Russian Direct Investment Fund (RDIF) and the Gemaleya National Research Center of Epidemiology and Microbiology, which was registered on 11 August. “This is a significant development, which allows us to start clinical trials in India and we bring a safe and effective vaccine to combat the epidemic,” GV0 Prasad, co-chairman and managing director of Dr. Reddy’s Laboratories said in a statement. Committed to. The Russian Direct Investment Fund (RDIF) said in a statement issued in this regard, RDIF will supply 10 million doses of vaccine to Dr. Reddy Laboratories based on regulatory permission in India.
The statement further stated that the Sputnik-5 vaccine is undergoing clinical trials for the coronavirus epidemic. Delivery can begin in late 2020, after successful testing and completion of registration of the vaccine by regulatory authorities in India. RDIF said that its agreement with Dr. Reddy Laboratories demonstrates that countries and organizations are conscious of protecting their people from the coronavirus epidemic.
A joint statement issued by Dr Reddy’s and the Russian Direct Investment Fund (RDIF) said, ‘This will be a multi-center and controlled study, which will include safety and immunological studies.’ Significantly, Sputnik V was tested in Russia on fewer people before it was registered as a vaccine, so DCGI questioned Dr Reddy’s initial proposal of testing among a large population in India. But it is currently being tested on 40,000 participants.
Sputnik V vaccine has been developed jointly by RDIF and Gamalaya National Research Center of Epidemiology and Microbiology. Russia allowed Sputnik-V, the first vaccine of the corona virus, the first corona vaccine worldwide. After this, Russia has approved the second corona vaccine EpiVacCorona on 14 October.